ArticleChembiochem : a European journal of chemical biology2025
Development of Granzyme A Turn-ON Fluorescent Activity-Based Probes.
Article in Chembiochem : a European journal of chemical biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Development of Granzyme A Turn-ON Fluorescent Activity-Based Probes.Chembiochem : a European journal of chemical biology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Granzyme A (GzmA), a serine protease highly expressed in cytotoxic immune cells, plays complex roles in antitumor immunity and inflammation. While elevated GzmA levels correlate with favorable outcomes in certain cancers, extracellular GzmA has been implicated in promoting tumorigenesis via inflammatory pathways. These contrasting functions highlight the need for selective tools that can detect GzmA activity with high spatiotemporal resolution in native biological contexts. A series of quenched activity-based probes that fluoresce only upon covalent binding to active GzmA have been developed. The lead probe, featuring the Ile-Gly-Asn-Arg recognition sequence, a phenyl phosphinate ester warhead, and a near-infrared sulfo-Cy5/QSY21 fluorophore/quencher pair, exhibits high reactivity, selectivity, and cell permeability. It enables robust detection of GzmA in vitro and in cells, with an excellent signal-to-noise ratio. These activatable probes will support downstream activity-based protein profiling and enable noninvasive imaging of the enzyme activity, offering a powerful means for dissecting the multifaceted biology of GzmA within the tumor immune microenvironment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.